Mundipharma Research Limited is a global, limited company focused on research and development, operating primarily within the fields of medical sciences and pharmaceutical development. Established in 2002, the company maintains a registered address at Unit 191 Cambridge Science Park in Cambridge, CB4 0GW, UK. Mundipharma specializes in providing expertise and services to pharmaceutical companies, particularly in the areas of oncology, neurology, and cardiovascular disease. The company’s core business revolves around the discovery, development, and commercialization of novel drug candidates and innovative therapies. Mundipharma’s expertise spans preclinical research, clinical trials, and regulatory affairs, supporting clients throughout the drug development lifecycle. They offer a range of services including target identification, assay development, preclinical studies, and clinical trial management. Mundipharma’s international presence is significant, with a dedicated team operating across Europe, North America, and Asia. The company’s size is estimated to be between 50-100 employees, and its key focus is on strategic research and collaborative partnerships. Mundipharma actively seeks skilled workers to contribute to its ongoing projects. The company is a type of limited company, and its SIC codes include: - 72190: Other research and experimental development on natural sciences and engineering.

Mundipharma Research Limited is a global, limited company focused on research and development, operating primarily within the fields of medical sciences and pharmaceutical development. Established in 2002, the company maintains a registered address at Unit 191 Cambridge Science Park in Cambridge, CB4 0GW, UK. Mundipharma specializes in providing expertise and services to pharmaceutical companies, particularly in the areas of oncology, neurology, and cardiovascular disease. The company’s core business revolves around the discovery, development, and commercialization of novel drug candidates and innovative therapies. Mundipharma’s expertise spans preclinical research, clinical trials, and regulatory affairs, supporting clients throughout the drug development lifecycle. They offer a range of services including target identification, assay development, preclinical studies, and clinical trial management. Mundipharma’s international presence is significant, with a dedicated team operating across Europe, North America, and Asia. The company’s size is estimated to be between 50-100 employees, and its key focus is on strategic research and collaborative partnerships. Mundipharma actively seeks skilled workers to contribute to its ongoing projects. The company is a type of limited company, and its SIC codes include: - 72190: Other research and experimental development on natural sciences and engineering.